Loading...

GRI GRI BIO INC Product Launches 8-K Filing

GR B

GR

GRI BIO INC

(GRI)

2025 8-K

Show Summary

Summary

New Product Launches

Equity Offerings

Financial Statements

Equity Offerings

Financial Results

Nasdaq Compliance

Stock Split Approval

Share Issuance Increase

Financial Results

Fundraising Announcement

Warrant Repricing

Nasdaq Compliance

Nasdaq Compliance Notice

Annual Meeting Results

Financial Results

Delisting Compliance

Public Offering

Amendment to Employment Agr...

Reverse Stock Split

Special Meeting of Stockhol...

Agreement for Stock Offering

Financial Results Announcement

Financial Results Announcement

Securities Purchase Agreement

Reverse Stock Split

Special Meeting of Stockhol...

Virtual Investor CEO Corner...

Delisting Notice

Delisting Notice

Financial Results Announcement

Virtual Investor Event

Asset Purchase Agreement

Financial Results Announcement

Regulation FD Disclosure

Merger and Reverse Stock Split

Special Meeting of Stockhol...

Special Meeting Adjournment

Merger Agreement

Merger Agreement and Supple...

Notice of Delisting

Financial Results Announcement

Participation Announcement

External Links:

On June 26, 2025, GRI Bio, Inc. announced its interim safety results from a Phase 2a study of GRI-0621 aimed at treating idiopathic pulmonary fibrosis. This filing serves to inform investors about the ongoing clinical study results.

AI Assistant

GRI BIO INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.